Overcoming multidrug-resistant lung cancer by mitochondrial-associated ATP inhibition using nanodrugsopen access
- Authors
- Park, Jun-Young; Lee, Gyu-Ho; Yoo, Kwai Han; Khang, Dongwoo
- Issue Date
- Jan-2023
- Publisher
- BMC
- Keywords
- Carbon nanotube; Doxorubicin; Endosomal escape; Multidrug resistant cell; Small cell lung cancer; Mitochondrial damage
- Citation
- JOURNAL OF NANOBIOTECHNOLOGY, v.21, no.1
- Journal Title
- JOURNAL OF NANOBIOTECHNOLOGY
- Volume
- 21
- Number
- 1
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/86971
- DOI
- 10.1186/s12951-023-01768-8
- ISSN
- 1477-3155
- Abstract
- Despite the development of therapeutic modalities to treat cancer, multidrug resistance (MDR) and incomplete destruction of deeply embedded lung tumors remain long-standing problems responsible for tumor recurrence and low survival rates. Therefore, developing therapeutic approaches to treat MDR tumors is necessary. In this study, nanodrugs with enhanced intracellular drug internalization were identified by the covalent bonding of carbon nanotubes of a specific nano size and doxorubicin (DOX). In addition, carbon nanotube conjugated DOX (CNT-DOX) sustained in the intracellular environment in multidrug-resistant tumor cells for a long time causes mitochondrial damage, suppresses ATP production, and results in the effective therapeutic effect of drug-resistant tumors. This study identified that H69AR lung cancer cells, an adriamycin (DOX) drug-resistant tumor cell line, did not activate drug resistance function on designed nano-anticancer drugs with a specific nano size. In summary, this study identified that the specific size of the nanodrug in combination with DOX overcame multidrug-resistant tumors by inducing selective accumulation in tumor cells and inhibiting ATP by mitochondrial damage.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의예과 > 1. Journal Articles
- 의과대학 > 의학과 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.